TOP2A and cancer: Doxorubicin, which is an anthracycline drug, was the first FDA approved agent targeting TOP2 and is currently used for the treatment of many cancers, including ALL (Acute lymphoblastic leukaemia) and AML (acute myeloid leukaemia), Wilms’ tumour, neuroblastoma, breast, ovarian, thyroid, gastric, Hodgkin’s disease, malignant lymphoma and bronchogenic carcinoma [233,238].